Abstract:Objective: To investigate the effect and mechanisms of KPT-330 on cell apoptosis of human leukemia cells. Methods: CCK-8 assay was used to quantify the growth inhibition of cells after exposure to KPT-330 for 24 hours. Fluorescence microscope was used to observe the morphological change of leukemia cell when treated with KPT330 for 24 hours. Annexin V/propidium iodide staining followed by flow cytometric analysis was used to detect apoptosis of leukemia cells. Then Western blot was used to detect the expression level of CRM1 and the activation of apoptosis related protein Caspase-9、Caspase-3 and PARP level. LncRNA microarray was used to analyze the differentially expressed genes from the cluster analyses. Results: The inhibition of cell proliferation of leukemia cells was in a dose-dependent manner and KPT-330 treatment induced expression of CRM1 down-regulated .Abnormal cells were observed under fluorescence microscopy. Cell apoptosis, cell cycle and activation of apoptosis markers demonstrates that KPT-330 induced apoptosis in leukemia cells. LncRNA microarray analysis showed differently expressed mRNAs and lncRNAs in KPT-330 treated HL-60 cells compared with control group. Molecular function analysis showed that KPT-330 induced apoptosis in leukemia cells partially related with Glutathione metabolism and Toll-like receptor signaling pathway. Conclusion: In this study, KPT-330 treatment resulted in inhibition of cell proliferation and induction of apoptosis in leukemia cells. LncRNA microarray analysis showed differentially expressed genes and lncRNAs in KPT-330 treated HL-60 cells and we demonstrated that KPT-330 induced apoptosis in leukemia cells partially related with Glutathione metabolism and Toll-like receptor signaling pathway. These results may provide new clue about molecular mechanism of KPT-330 induced apoptosis; however, underlying details will be required to determine further. Taken together, our findings suggest that for the first time that KPT-330 may act as new candidate's drug for leukemia. Disclosures No relevant conflicts of interest to declare.

Regulation Of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression In Primary Acute Leukemic Cells By Chemotherapeutics

TRAIL and Cancer Therapy

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

The Investigation of the Relationship Between Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Tumor Therapy

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Sensitivity of T-cell Acute Lymphoblastic Leukemia to TRAIL Induced Apoptosis

Experimental Study on Apoptosis of Osteosarcoma Cell Induced by TRAIL Combined with IFN-γ

Tumor Necrosis Factor–related Apoptosis-Inducing Ligand Induces the Expression of Proinflammatory Cytokines in Macrophages and Re-Educates Tumor-Associated Macrophages to an Antitumor Phenotype

Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis in NSCLC Cells

Pro-Inflammatory Activation Suppresses TRAIL-induced Apoptosis of Acute Myeloid Leukemia Cells

Effective Chemotherapy Induce Apoptosis in Vivo in Patients with Leukemia

Mechanism of TRAIL Induced Tumor Cell Apoptosis and Application of TRAIL Based on Tumor Therapy

TRAIL Triggers CRAC-Dependent Calcium Influx and Apoptosis through the Recruitment of Autophagy Proteins to Death-Inducing Signaling Complex

Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment

The Difference in Inducing Apoptosis of Leukemic Cell Lines by Recombinant Human Soluble TNF-related Apoptosis Inducing Ligand(rhstrail)

Molecular Mechanism Analysis the Apoptosis of Leukemia Cells Induced by CRM1 Selective Inhibitor KPT-330

Tumor necrosis factor-related apoptosis-inducing ligand modulates angiogenesis and apoptosis to inhibit non-small cell lung carcinoma tumor growth in mice

Tunicamycin Sensitizes Acute Lymphoblastic Leukemia Cell Line with 11q23 Abnormality to TRAIL Induced Apoptosis: an Invitro Study

Developing TRAIL/TRAIL death receptor-based cancer therapies

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies